FFO
NRIX icon

Fortitude Family Office’s Nurix Therapeutics NRIX Stock Holding History

Fortitude Family Office’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$481 Buy
+31
New +$514 ﹤0.01% 1745

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Fortitude Family Office's NRIX Position: Q1 2026 in Review

Fortitude Family Office opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 31 shares worth $481. The stake represents ﹤0.01% of the portfolio and ranks #1745 among its holdings.

195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Fortitude Family Office held 31 shares of Nurix Therapeutics worth $481 as of Q1 2026.
  • Nurix Therapeutics was a new Fortitude Family Office position in Q1 2026.
  • Nurix Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #1745 holding.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.